Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | DRD1 | P21728 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16248309 | 1.00 | MAPT (0.47) | MAPTDRD1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12786268 | 0.85 | DRD1 (0.36) | MAPTDRD1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3415364 | 0.82 | NPC1 (0.58) | MAPTDRD1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1111225 | 0.82 | DRD1 (0.35) | MAPTDRD1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30220116 | 0.82 | DRD1 (0.35) | MAPTDRD1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13991583 | 0.82 | MAPK1 (0.40) | MAPTDRD1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15478440 | 0.82 | DRD1 (0.35) | MAPTDRD1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3954455 | 0.82 | NPC1 (0.58) | MAPTDRD1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1111229 | 0.82 | DRD1 (0.35) | MAPTDRD1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29528319 | 0.82 | DRD1 (0.35) | MAPTDRD1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213081-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-07-07 | — | — | US | disclosed |
| US-20220119377-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-04-21 | — | — | US | disclosed |
| US-11214568-B2 | Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-01-04 | — | — | US | disclosed |
| US-20200199114-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2020-06-25 | — | — | US | disclosed |
| WO-2020117894-A1 | ISOCARBOSTYRIL ALKALOIDS AND FUNCTIONALIZATION THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-06-11 | — | — | WO | disclosed |
| US-10336737-B2 | Metal catalyzed dearomative 1,2-carboamination | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336737-B2 | Metal catalyzed dearomative 1,2-carboamination | DNTT, DIMT1, NMT1 | MAPT 4331/4885DRD1 370/4885NPC1 1911/4885 |
| US-20220213081-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | GMNN, GRIA1, GRIA2 | MAPT 2373/4885DRD1 434/4885NPC1 3777/4885 |
| US-20200199114-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | GMNN, GRIA1, GRIA2 | MAPT 2373/4885DRD1 434/4885NPC1 3777/4885 |
| US-20220119377-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | GMNN, GRIA1, GRIA2 | MAPT 2373/4885DRD1 434/4885NPC1 3777/4885 |
| US-11214568-B2 | Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same | GMNN, GRIA1, GRIA2 | MAPT 2373/4885DRD1 434/4885NPC1 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.